BioMarin’s Voxzogo Sales Forecast Rises Despite Supply Constraints

Voxzogo’s success is posing challenges for BioMarin.

Here’s what you need to know:

• BioMarin’s drug, Voxzogo, is performing better than expected, resulting in a bottleneck in the product’s fill-finish capacity.
• The product exceeded sales forecasts and became a significant growth contributor for the company.
• Voxzogo’s sales increased 229% to $113.3 million in the second quarter of 2023.
• Supply issues have limited Voxzogo’s growth, primarily caused by fill-finish capacity constraints from a third-party service.
• BioMarin expects to resolve the supply issues by 2025, with improvements starting the following year.
• Despite supply challenges, BioMarin increased its forecasted sales for Voxzogo to a range of $400 million to $440 million.
• BioMarin’s CEO predicts the company can comfortably exceed the current market consensus for Voxzogo in 2024.

To read more, click here.